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Objectives The aim of this study was to analyse baseline 
characteristics and outcome of patients with heart failure 
and mid-range left ventricular ejection fraction (HFmrEF, 
left ventricular ejection fraction (LVEF) 40%–49%) and the 
effect of 1-year change in LVEF in this group.
setting Multicentre prospective observational study of 
ambulatory patients with HF followed up at four university 
hospitals with dedicated HF units.
Participants Fourteen per cent (n=504) of the 3580 
patients included had HFmrEF.
Interventions Baseline characteristics, 1-year LVEF 
and outcomes were collected. All-cause death, HF 
hospitalisation and the composite end-point were the 
primary outcomes.
results Median follow-up was 3.66 (1.69–6.04) years. 
All-cause death, HF hospitalisation and the composite end-
point were 47%, 35% and 59%, respectively. Outcomes 
were worse in HF with preserved ejection fraction (HFpEF) 
(LVEF>50%), without differences between HF with reduced 
ejection fraction (HFrEF) (LVEF<40%) and HFmrEF (all-
cause mortality 52.6% vs 45.8% and 43.8%, respectively, 
P=0.001). After multivariable Cox regression analyses, no 
differences in all-cause death and the composite end-point 
were seen between the three groups. HF hospitalisation 
and cardiovascular death were not statistically different 
between patients with HFmrEF and HFrEF. At 1-year follow-
up, 62% of patients with HFmrEF had LVEF measured: 
24% had LVEF<40%, 43% maintained LVEF 40%–49% and 
33% had LVEF>50%. While change in LVEF as continuous 
variable was not associated with better outcomes, those 
patients who evolved from HFmrEF to HFpEF did have 
a better outcome. Those who remained in the HFmrEF 
and HFrEF groups had higher all-cause mortality after 
adjustment for age, sex and baseline LVEF (HR 1.96 (95% 
CI 1.08 to 3.54, P=0.027) and HR 2.01 (95% CI 1.04 to 
3.86, P=0.037), respectively).
Conclusions Patients with HFmrEF have a clinical profile 
in-between HFpEF and HFrEF, without differences in all-
cause mortality and the composite end-point between the 
three groups. At 1 year, patients with HFmrEF exhibited the 
greatest variability in LVEF and this change was associated 
with survival.
IntrOduCtIOn
Despite the improvement in knowledge and 
treatment of heart failure (HF) in the last 
decades, HF is still a prevalent disease with 
a bad prognosis1 and to which considerable 
healthcare resources are dedicated.2 Much of 
the research to date has focused on patients 
with HF and reduced ejection fraction 
(HFrEF) and so far pharmacological and inva-
sive treatments have only shown to be useful 
strengths and limitations of this study
 ► Cohort study of patients with heart failure (HF) 
followed up at four hospitals with a dedicated HF 
unit, thereby reflecting different clinical practice 
within guidelines recommendations.
 ► The hospitals varied from community-oriented 
hospitals to reference centres with transplant 
and ventricular assist devices programmes. The 
inclusion of hospitals with different levels of 
complexity determined that baseline characteristics 
of patients were different among the four hospitals, 
which allows an easier generalisation of the results.
 ► Not all patients had an echocardiogram during 
follow-up, which might have resulted in a bias and 
affected the results.
2 Farré N, et al. BMJ Open 2017;7:e018719. doi:10.1136/bmjopen-2017-018719
Open Access 
in this group of patients.3 Furthermore, definition of HF 
with preserved ejection fraction (HFpEF) varies widely 
in registries and in randomised controlled trials (from 
left ventricular ejection fraction (LVEF)>40% to >55%)4 
and hence a grey zone of patients with LVEF ranging 
40%–50% has hardly been studied. For this reason, the 
last 2016 European Society of Cardiology (ESC) Guide-
lines for the diagnosis and treatment of acute and chronic 
HF included this new mid-range group in the classifica-
tion of HF in order to stimulate research in this subpop-
ulation of patients.3 Previous studies have shown that 
patients with HF and mid-range left ventricle ejection 
fraction (HFmrEF) have a baseline profile in-between 
of HFrEF and HFpEF, with some characteristics closer 
to HFrEF (predominant ischaemic aetiology) and others 
to HFpEF (higher prevalence of women and elderly 
patients). Moreover, differences in outcomes have also 
been described between groups. Given the differences 
in baseline characteristics and prognosis in the three 
groups, some authors suggest that HFmrEF has a pheno-
type closer to HFpEF5–8 whereas other authors consider it 
closer to HFrEF.9–11 In patients with HFrEF (LVEF<40%) 
an improvement in LVEF has been associated with better 
outcomes.12 Whether this is also true in patients with 
mid-range EF (HFmrEF) is unknown.
Hence, the aim of this study was to analyse the base-
line characteristics and outcome of patients with HFmrEF 
compared with patients with HFpEF (LVEF >50%) and 
HFrEF and to analyse the effect of 1 year change in LVEF 
in patients with HFmrEF on outcome.
MethOds
study population
This was a prospective observational study of patients 
with HF followed at four university hospitals with a 
dedicated Heart Failure Unit. Patients were consecu-
tively enrolled from August 2001 to June 2015 and HF 
was diagnosed following the ESC guidelines.3 Baseline 
demographic, clinical and echocardiographic data were 
collected. Patients were classified into three groups 
according to the new ESC Guidelines for the diagnosis 
and treatment of acute and chronic HF: HFrEF, HFmrEF 
and HFpEF.3 Changes in medical therapy over time were 
not collected.
Data on 1-year LVEF were also collected when available. 
Follow-up echocardiograms were performed as per each 
institutional protocol. All patients were followed up at 
regular intervals. Those who failed to attend the clinic 
appointment were contacted by telephone, and hospital 
and primary care records were reviewed in order to assess 
vital status and HF hospitalisations. The main outcome 
was recorded as death from all causes, HF hospitalisation 
and a composite end-point of all-cause death and HF 
hospitalisation. Cardiovascular (CV) death was also anal-
ysed. A death was considered of CV origin if it was caused 
by HF, sudden death, acute myocardial infarction, stroke, 
CV procedures or other CV causes.
All patients gave written informed consent during the 
initial visit.
statistical analyses
Continuous variables were expressed as mean±SD or 
median and IQR, depending on whether data distri-
bution was normal (assessed by normal Q–Q plots); 
categorical variables were expressed as percentages. 
A comparative analysis between variables was carried out 
using χ² test (categorical variables) and Student’s t-test 
or Mann–Whitney U-test, one-way analysis of variance 
or Kruskal-Wallis test for continuous variables. P value 
adjustment for multiple testing was performed by Tukey 
(normal-distribution) or Benjamini and Hochberg 
method (otherwise). Kaplan-Meier survival curves were 
compared by the log-rank test. Multivariate analysis was 
performed using Cox proportional hazard regression 
(Cox) including centre as strata.
In all analyses involving CV death and HF hospitalisa-
tion, a competing risks strategy by the Gray method was 
adopted,13 considering non-CV death as the competing 
event for CV death and all-cause death for HF hospitalisa-
tion. HFrEF was used as the reference category. The anal-
yses were performed with R (V.3.3.2) R: A Language and 
Environment for Statistical Computing (Vienna, Austria). 
We considered P values <0.05 from two-sided tests to indi-
cate statistical significance.
In all analyses involving CV, HF-related and sudden 
death, competing risk strategy by the Gray method was 
adopted, considering non-CV death as the competing 
event for CV death and other CV death and non-CV 
death for HF-related and sudden death. The category 
‘HF-recovered’ was used as a reference. Survival curves 
for all-cause death and cumulative incidence curves for 
the composite primary endpoint, and CV, HF-related and 
sudden death were plotted. P-values were obtained using 
log-rank and Gray method, respectively.
results
baseline clinical characteristics
Baseline clinical characteristics and treatment were cate-
gorised according to LVEF and are summarised in table 1. 
Fourteen per cent (n=504) of the 3580 patients included 
in the study had HFmrEF, 62% had HFrEF and 24% 
HFpEF. In the whole cohort, mean age was 68±13 years, 
62% were men and mean LVEF was 38%±16%. Baseline 
characteristics of patients with HFmrEF were in-between 
those of HFpEF and HFrEF. Use of neurohormonal treat-
ment was higher in patients with HFrEF and HFmrEF, 
whereas the use of loop diuretics was highest in the 
HFpEF group. The four cohorts were clinically different 
(see online supplementary material, table S1, describing 
the baseline characteristics according to hospital).
Follow-up events
During a median follow-up of 3.66 (1.69–6.04) years, 
all-cause death, HF hospitalisation and the composite 
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end-point were 47%, 35% and 59%, respectively 
(table 2). The cause of death was CV in 24.7% of patients, 
without differences in the three groups (overall P=0.068). 
Outcomes were worse in HFpEF, without differences 
between HFrEF and HFmrEF (figure 1). In multivari-
able Cox regression analyses, no differences in all-cause 
death and composite end-point were seen between the 
three groups. HF hospitalisation and CV death were not 
statistically different between patients with HFmrEF and 
HFrEF, although a tendency (P=0.068) towards a lower 
CV mortality in HFmrEF was observed (table 3). On the 
other hand, patients with HFpEF had significantly higher 
HF hospitalisation and lower CV death (table 3).
Changes in lVeF
Flowchart of patients according to the change of LVEF 
is depicted in figure 2. Of the 1971 patients with HFrEF 
alive at 1 year, 67% had an echocardiogram performed: 
62% still had LVEF<40% and 21% had LVEF 40%–50%. 
In this group, after adjustment for age, sex and baseline 







(24%) P value* P value** P value*** N
Male 2397 (67.0) 1689 (75.7) 337 (66.9) 371 (44.0) <0.001 <0.001 <0.001 3580
Age 68.2±12.7 66.2±12.5 68.1±12.9 73.5±11.4 <0.001 0.003 <0.001 3580
LVEF 38.3±16.0 28.0±6.9 43.5±2.9 62.5±8.3 <0.001 <0.001 <0.001 3580
Aetiology: <0.001 <0.001 <0.001 3579
Ischaemic 1600 (44.7) 1174 (52.6) 261 (51.8) 165 (19.5)
Dilated 552 (15.4) 450 (20.2) 58 (11.5) 44 (5.21)
Hypertensive 592 (16.5) 169 (7.58) 72 (14.3) 351 (41.6)
Valvular 321 (8.97) 131 (5.87) 45 (8.93) 145 (17.2)
Other 514 (14.4) 307 (13.8) 68 (13.5) 139 (16.5)
Heart rate 72.7±14.8 72.8±14.9 70.8±14.3 73.8±14.6 0.001 0.005 <0.001 3577
Hypertension 2485 (69.4) 1434 (64.2) 366 (72.6) 685 (81.2) <0.001 <0.001 <0.001 3580
Diabetes mellitus 1547 (43.2) 956 (42.8) 210 (41.7) 381 (45.1) 0.386 0.669 0.235 3580
COPD 721 (20.1) 427 (19.1) 103 (20.4) 191 (22.6) 0.096 0.544 0.381 3580
Dyslipidaemia 1843 (51.5) 1158 (51.9) 263 (52.2) 422 (50.0) 0.611 0.942 0.472 3580
Atrial fibrillation 999 (27.9) 435 (19.5) 158 (31.3) 406 (48.2) <0.001 <0.001 <0.001 3579
BMI, kg/m2 27.8±5.30 27.3±4.93 28.2±5.30 28.9±6.01 <0.001 <0.001 0.045 3528
Sodium, mmol/L 139±4.33 139±4.67 140±3.50 140±3.63 <0.001 <0.001 0.730 3556
Anaemia 1231 (34.9) 656 (29.9) 184 (37.1) 391 (46.8) <0.001 0.002 0.001 3580
NT-proBNP, ng/L 1638 (697;3937) 1898 (769;4465) 1484 (532;3866) 1320 (635;2818) <0.001 <0.001 0.518 2705
eGFR, mL/
min/1.73 m2
60.4±25.4 62.4±25.4 60.4±26.5 55.2±23.8 <0.001 0.125 <0.001 3562
NYHA class III–IV 1293 (36.1) 746 (33.4) 172 (34.1) 375 (44.4) <0.001 0.808 <0.001 3579
Treatment:
ACEI or ARB 2992 (83.9) 1992 (89.5) 412 (82.1) 588 (70.1) <0.001 <0.001 <0.001 3567
Beta-blockers 3094 (86.4) 2040 (91.4) 448 (88.9) 606 (71.8) <0.001 0.092 <0.001 3580
MRA 1890 (52.8) 1447 (64.8) 219 (43.5) 224 (26.5) <0.001 <0.001 <0.001 3580
Loop diuretics 3189 (89.1) 2002 (89.7) 423 (83.9) 764 (90.5) <0.001 <0.001 <0.001 3580
Digoxin 959 (27.7) 675 (30.8) 106 (21.7) 178 (22.5) <0.001 <0.001 0.788 3467
ICD 396 (11.1) 359 (16.1) 26 (5.16) 11 (1.31) <0.001 <0.001 <0.001 3578
CRT 234 (6.54) 213 (9.54) 16 (3.17) 5 (0.59) <0.001 <0.001 0.001 3580
Anticoagulants 1684 (47.0) 969 (43.4) 239 (47.4) 476 (56.4) <0.001 0.113 0.002 3580
Data are mean±SD deviation, median (IQR) or n (%). Anaemia was defined as a haemoglobin<12 g/dL.
*P values for the comparison of all three groups (null hypothesis: all three groups have the same characteristics).
**P value only applies to the comparison of HFrEF vs HFmrEF.
***P value only applies to the comparison of HFpEF vs HFmrEF.
ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRT, 
cardiac resynchronisation therapy; eGFR, estimated glomerular filtration rate (CKD-EPI equation); HFmrEF, heart failure with mid-range 
left ventricle ejection fraction; HFpEF, heart failure with preserved left ventricle ejection fraction; HFrEF, heart failure with reduced left 
ventricle ejection fraction; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor 
antagonists; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York  Heart  Association. 
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EF, HRs for survival for change in LVEF was 0.97 (95% CI 
0.96 to 0.98, P<0.001).
LVEF of patients with HFmrEF (analysed in 61% of the 
438 patients alive at 1 year) had the greatest variation: 24% 
had reduced LVEF, 43% maintained LVEF 40%–49% and 
33% had LVEF >50%. Figure 3 shows Kaplan-Meier curves 
for long-term outcome for changes of LVEF in HFmrEF. 
There were no differences in mortality between patients 
who remained in HFmrEF group and those who changed 
to HFrEF, while survival was significantly higher in those 
patients who evolved to the HFpEF group (P=0.026). 
Compared with patients whose LVEF improved enough 
to move to the HFpEF group, those who remained in 
the HFmrEF and HFrEF had higher all-cause mortality 
after adjustment for age, sex and baseline LVEF (HR 1.96 
(95% CI 1.08 to 3.54, P=0.027) and HR 2.01 (95% CI 1.04 
to 3.86, P=0.037), respectively). As a continuous variable, 
however, and after adjustment for age, sex and base-
line LVEF, HR for survival for change in LVEF was 0.99 
(95% CI 0.96 to 1.01, P=0.229). Baseline characteristics 
of patients who evolved to HFpEF were similar to those 
who remained in HFmrEF or changed to HFrEF, except 
for a higher proportion of women (38% vs 23%, P=0.021) 
and non-ischaemic aetiology (61% vs 38%, P=0.001), 
higher diastolic blood pressure (76±11 vs 72±12 mm Hg, 
P=0.009) and estimated glomerular filtration rate 
(70±24 vs 63±27 mL/min, P=0.028) but lower N-terminal 
pro-brain natriuretic peptide (NT-proBNP) (901 (450–
1690) ng/L vs 1494 (593–4456], P=0.013). Baseline LVEF 
was higher (44%±3% vs . 42±2%, p<0.001). Interestingly, 
treatment was similar in both groups, with a high use of 
beta blockers (95.5% vs 92.3%, P=0.470), ACE inhibitor/







n=844 (24%) P value* P value** P value*** N
All-cause death 1688 (47.2) 1023 (45.8) 221 (43.8) 444 (52.6) 0.001 0.448 0.003 3580
Cause of death <0.001 0.164 0.011 3580
HF 458 (12.8) 269 (12.1) 58 (11.5) 131 (15.5)
Sudden death 126 (3.52) 101 (4.53) 13 (2.58) 12 (1.42)
Other cardiovascular 196 (5.47) 122 (5.47) 29 (5.75) 45 (5.33)
Non-cardiovascular 500 (14.0) 265 (11.9) 72 (14.3) 163 (19.3)
Unknown 408 (11.4) 266 (11.9) 49 (9.7) 93 (11.0)
HF hospitalisation 1259 (35.2) 724 (32.4) 157 (31.2) 378 (44.8) <0.001 0.613 <0.001 3580
Composite end-point 2113 (59.0) 1277 (57.2) 272 (54.0) 564 (66.8) <0.001 0.201 <0.001 3580
Data are n (%).
*P values for the comparison of all three groups (null hypothesis: all three groups have the same characteristics).
**P value only applies to the comparison of HFrEF vs HFmrEF.
***P value only applies to the comparison of HFpEF vs HFmrEF.
HF, heart failure; HFmrEF, heart failure with mid-range left ventricle ejection fraction; HFpEF, heart failure with preserved left ventricle ejection 
fraction; HFrEF, heart failure with reduced left ventricle ejection fraction. 
Figure 1 Kaplan-Meier curves for long-term outcome divided by LVEF (A, cumulative survival; B, HF hospitalisation-free 
cumulative incidence; C, composite end-point cumulative survival). HF, heart failure; LVEF, left ventricular ejection fraction.
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angiotensin II receptor blocker (83% vs 83%, P=1.0) and 
mineralocorticoid receptor antagonists (40.9% vs 51.9%, 
P=0.117). See online supplementary material (table S2) 
for comparison among the groups.
Finally, among patients with HFpEF alive at 1 year, only 
288 (40%) had LVEF measured at 1-year follow-up, and 
the majority (85%) of them still had LVEF >50%. After 
adjustment for age, sex and baseline EF, HR for survival 
Table 3 Multivariable Cox regression analyses with hospital as strata for all-cause death, HF hospitalisation, composite end-
point and cardiovascular death
All-cause death HF hospitalisation
Composite end-point
(all-cause 
death+HF hospitalisation) CV death
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
HFrEF 1 (ref) 1 (ref) 1 (ref) 1 (ref)
HFmrEF 0.93 (0.80 to 1.08) 0.338 1.00 (0.84 to 1.20) 0.98 0.94 (0.82 to 1.07) 0.358 0.80 (0.64 to 1.01) 0.061
HFpEF 0.93 (0.81 to 1.06) 0.265 1.18 (1.02 to 1.38) 0.032 0.95 (0.84 to 1.06) 0.362 0.75 (0.62 to 0.92) 0.006
Female 0.75 (0.67 to 0.84) <0.001 – 0.85 (0.77 to 0.94) 0.002 0.75 (0.64 to 0.88) <0.001
Age 1.03 (1.03 to 1.04) <0.001 – 1.02 (1.02 to 1.03) <0.001 1.03 (1.02 to 1.04) <0.001
Heart rate 1.00 (1.00 to 1.01) 0.013 – 1.00 (1.00 to 1.01) 0.008 –
DBP 0.99 (0.99 to 1.00) 0.002 0.99 (0.99 to 1.0) 0.044 0.99 (0.99 to 1.00) 0.001 0.99 (0.98 to 0.99) <0.001
Dyslipidaemia 0.86 (0.78 to 0.96) 0.004 1.25 (1.10 to 1.41) <0.001 – –
DM 1.30 (1.17 to 1.44) <0.001 1.22 (1.08 to 1.37) 0.002 1.27 (1.16 to 1.39) <0.001 1.27 (1.11 to 1.47) <0.001
COPD 1.32 (1.17 to 1.48) <0.001 1.27 (1.10 to 1.47) <0.001 1.30 (1.17 to 1.45) <0.001 –
BMI 0.98 (0.97 to 0.99) <0.001 – – –
Sodium – – – 0.99 (0.97 to 1.00) 0.024
Haemoglobin 0.93 (0.90 to 0.96) <0.001 0.90 (0.87 to 0.93) <0.001 0.91 (0.89 to 0.93) <0.001 0.93 (0.89 to 0.97) 0.001
eGFR 0.99 (0.99 to 1.00) <0.001 0.99 (0.99 to 0.99) <0.001 0.99 (0.99 to 1.00) <0.001 0.99 (0.99 to 0.99) <0.001
NYHA class III–IV 1.62 (1.46 to 1.80) <0.001 1.34 (1.18 to 1.51) <0.001 1.54 (1.40 to 1.69) <0.001 1.61 (1.39 to 1.86) <0.001
ACEI or ARB 0.70 (0.62 to 0.81) <0.001 – 0.74 (0.65 to 0.83) <0.001 –
Beta-blockers 0.60 (0.53 to 0.69) <0.001 – 0.70 (0.62 to 0.79) <0.001 0.60 (0.49 to 0.72) <0.001
Loop diuretics 1.28 (1.04 to 1.57) 0.020 2.97 (2.18 to 4.06) <0.001 1.61 (1.33 to 1.94) <0.001 1.88 (1.32 to 2.67) <0.001
CRT 0.70 (0.55 to 0.89) 0.003 – – –
ICD – – – 0.77 (0.60 to 0.98) 0.032
MRA – 1.18 (1.03 to 1.34) 0.014 – –
Digoxin – 1.48 (1.29 to 1.69) <0.001 – 1.26 (1.08 to 1.47) 0.004
Anticoagulants – – – –
Hypertension – – 1.12 (1.01 to 1.25) 0.033 –
ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronisation 
therapy; CV, cardiovascular; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate (CKD-EPI equation); HF, heart failure; 
HFmrEF, HF with mid-range left ventricle ejection fraction; HFpEF, HF with preserved left ventricle ejection fraction; HFrEF, HF  with reduced left ventricle ejection 
fraction; ICD, implantable cardioverter defibrillator;  MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association.
Figure 2 Flowchart of patients according to the change of LVEF. LVEF, left ventricular ejection fraction.
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for change in LVEF in this group was 0.99 (95% CI 0.97 
to 1.01, P=0.283).
Interestingly, at 1-year follow-up, 22.9% of patients were 
in the HFmrEF category, irrespective of their initial LVEF.
dIsCussIOn
Patients with HFmrEF are a small group in the spectrum 
of patients with HF and their clinical characteristics did 
not allow differentiating them from patients with HFpEF 
or HFrEF. Moreover, all-cause mortality was not different 
from that of HFpEF or HFrEF. CV mortality, however, 
tended to be lower in patients with HFmrEF than in 
patients with HFrEF. Interestingly, change in 1-year LVEF 
in this group was broader (24% had a decrease in LVEF 
and 33% had LVEF>50%). While change in LVEF frac-
tion as continuous variable was not associated with better 
outcomes, those patients who evolve from HFmrEF to 
HFpEF actually did have a better outcome.
baseline clinical characteristics
Prevalence of HFmrEF in our study was 14%, similar 
to other studies carried out in hospitalised (prevalence 
between 13% and 26%)5–7 14 15 and ambulatory (9% and 
21%)9–11 16–18 patients with HF. Consistent with other 
studies, clinical characteristics of patients with HFmrEF 
did not allow for a clear clinical differentiation of this 
group. Age and prevalence of women were higher in 
HFmrEF than in HFrEF but lower than in HFpEF. This 
finding is consistent across different studies.5 7 8 10 14 16–19 
Some comorbidities such as diabetes mellitus, dyslipi-
daemia and chronic obstructive pulmonary disease were 
not different between the three groups. In patients with 
HFmrEF, the presence of anaemia, chronic kidney disease 
and New York Heart Association class III–IV was similar to 
those with HFrEF but was lower than in those with HFpEF. 
Interestingly, NT-proBNP was not different between 
HFmrEF and HFpEF but was lower than in HFrEF. Aeti-
ology of HF was also different between the three groups, 
with a predominant ischaemic cause in HFrEF and 
HFmrEF and hypertensive in HFpEF. Similar results 
have been described in other studies and, although some 
differences can be found in the distribution of comorbid-
ities among studies,5–10 14 16 17 19 20 the overall perception 
is that it is not possible to identify a clear pattern of clin-
ical characteristics that defines HFmrEF, but differences 
in aetiology, sex and age would point more to a patient 
with HFrEF.
Follow-up events
Given the differences in baseline characteristics and 
prognosis in the three groups, some authors suggest that 
HFmrEF has a phenotype closer to HFpEF5–8 whereas 
other authors consider it closer to HFrEF.9–11 All-cause 
mortality and HF hospitalisation were similar in HFrEF 
and HFmrEF (45.8% vs 43.8%, P=0.448) but were lower 
than in HFpEF (52.6%, overall P=0.002). However, in 
multivariable Cox regression analyses with competing 
risk, HFpEF performed worse than those with HFmrEF 
and HFpEF, relative to HF hospitalisation but had lower 
CV mortality. While some studies have shown no differ-
ences in outcomes among the three groups,5–7 10 14 other 
authors have found different results, with a higher 
mortality in HFmrEF compared with HFpEF in patients 
with ambulatory HF9 and, contrary to our results, a higher 
HF hospitalisation in HFrEF compared with HFmrEF and 
HFpEF.8 Interestingly, we found similar all-cause death 
Figure 3 Kaplan-Meier curves for long-term outcome for changes of LVEF in the HFmrEF (A, cumulative survival; B, HF 
hospitalisation-free cumulative incidence). HF, heart failure; HFmrEF, HF with mid-range left ventricle ejection fraction; LVEF, left 
ventricular ejection fraction.
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between patients with HFrEF and HFmrEF, but a trend 
towards lower CV mortality in the latter group.
Changes in lVeF
At 1-year follow-up, LVEF of patients with HFmrEF had 
the greatest variation: 24% had reduced LVEF, 43% 
maintained LVEF 40%–49% and 33% had LVEF >50%. 
Remarkably, in this group, change in LVEF as continuous 
variable was not associated with survival but when the 
improvement in LVEF was enough to move the patient 
from HFmrEF to HFpEF, survival improved signifi-
cantly. Women and non-ischaemic aetiology were more 
frequent in patients who moved to HFpEF and that has 
been shown in other studies.21 Although treatment has 
been associated with improvement in LVEF22–24 we did 
not see any difference in treatment between patients who 
moved to HFpEF and those who remained in HFmrEF or 
went to HFrEF. However, this lack of difference might be 
explained by the high use of Class I medications in our 
population.
The apparent paradox of absence of a clear difference 
in long-term prognosis in patients according to the three 
groups of LVEF can be plausibly disentangled. On the 
one hand, LVEF measured by echocardiography is an 
imperfect measure to determine left ventricular systolic 
function as it only captures one part of the whole biome-
chanics of cardiac function and exhibits important vari-
ability.25 Moreover, impairment of left ventricular systolic 
function is also present in patients with HFpEF, even 
though their LVEF might be normal.26 On the other 
hand, cut-offs used to define the three groups (HFrEF, 
HFmrEF and HFpEF) are arbitrary.3 Finally, LVEF is a 
dynamic measure that can vary with treatment22 23 and 
during follow-up.17 23 In the present study, 437 patients 
had HFmrEF according to the echocardiogram at 1-year 
follow-up. This represents an increase from 14% at base-
line to 22.9% at 1-year follow-up. Previous studies have 
shown that depending on the cut-off used (LVEF 40% vs 
50%), up to 50% of patients with HFpEF were patients 
with previously reduced LVEF27 28 and patients with 
recovered LVEF had a better prognosis compared with 
those with preserved or reduced LVEF20 21 24 27–29 and with 
those who did not improve LVEF.12 Although it was less 
frequent, patients with HFpEF also showed variability in 
LVEF during follow-up (only 15% of patients with HFpEF 
had LVEF <50% at 1-year follow-up in our study). Dunlay 
et al showed that among patients with HFpEF, 21.1% 
had an EF<50% around 1 year after diagnosis and this 
increased to 32.5% in those with an echo performed from 
4 to 6 years after diagnosis,24 and similar results were seen 
in other studies.18 22 In the present study, change in LVEF 
in HFpEF was not independently associated with all-cause 
mortality. In HFmrEF, patients whose LVEF improved 
enough to move to HFpEF, outcome was better but when 
LVEF did not move or worsened, prognosis was worse, 
consistently with other studies that showed that irrespec-
tive of baseline group, the transition to HFrEF was associ-
ated with increased all-cause mortality.18
Taken together, the results of the present and previous 
studies show that the classification of patients in HF with 
preserved, mid-ranged and reduced LVEF is not static. In 
other words, many patients with HFmrEF might be either 
recovered in patients with HFrEF or, probably to a lesser 
extent, patients with worsened HFpEF and this fact might 
explain the difficulty in clinically characterising them 
properly and might explain the lack of differences found 
in all-cause mortality between the three groups. Irrespec-
tive of the limitations, LVEF might have to classify patients 
with different prognosis, baseline echocardiogram has 
the crucial role to identify patients in whom disease modi-
fying treatment are useful to improve prognosis. Whether 
baseline LVEF or follow-up LVEF should be used to clas-
sify patients remains unclear.
limitations
Follow-up echocardiograms were not done at prespecified 
intervals in all patients. This might have been a source of 
bias because the decision to perform a follow-up echo-
cardiogram may have been influenced by clinical status, 
age and baseline LVEF. Table 3 (see online  supplemental 
material) shows the differences between patients who 
survived 1 year with and without an echocardiogram done 
at follow-up. We have added a table (see online supple-
mental material) showing the differences between patients 
with and without an echocardiogram done at follow-up. 
Patients without an echocardiogram at follow-up were 
older and had more comorbidity. This group of patients 
are more frequently not studied with echocardiogram.24 It 
might have been thought that no benefit would be derived 
from serial echocardiograms due to poor predicted 
outcome or presumed HFpEF. Conversely, patients with 
1-year follow-up echocardiogram had lower baseline LVEF 
and were more frequently on optimal medical therapy. 
In this group of patients, some recovery of LVEF may 
be expected and this may influence subsequent deci-
sions regarding implantable cardioverter defibrillator 
or  cardiac resynchronisation therapy suitability, there-
fore serial echocardiograms are more often done. Finally, 
Dunlay et al report that their patients had a median of 2 
echocardiograms during follow-up and mean time from 
initial to final EF measurement was around 3 years but these 
authors did not report how many patients had an echo-
cardiogram done at 1-year follow-up.24 In another study, 
43% of patients with a primary hospital discharge diag-
nosis for HF did not have two or more LVEF tests≥30 days 
apart during the study period.22 Hence, considering that 
in the present study two-thirds of patients had an echocar-
diogram done at 1-year follow-up, we think that results are 
consistent with common clinical practice.
NT-proBNP was missing in 25% of our patients and 
therefore this biomarker was not included in the multi-
variable analysis. Consistently with our results, van Veld-
huisen et al showed that BNP levels were lower in patients 
with HFpEF than in HFrEF. For a given BNP level, that 
study showed that the prognosis in patients with HFpEF 
was similar than those with reduced LVEF.30
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Finally, the baseline characteristics of the patients 
included in the four hospitals are remarkably different. 
Although that may be seen as a limitation, the inclusion 
of different type of patients with HF allowed us to better 
characterise this population, combining patients followed 
up in centres with different degree of specialisation 
(advanced HF centres and community oriented hospi-
tals), thus including patients that would have been lost 
if only centres with similar characteristics were analysed.
COnClusIOn
Patients with HFmrEF have a clinical profile in between 
HFpEF and HFrEF and there were no differences in 
all-cause mortality and the composite end-point between 
the three groups. At 1-year follow-up, patients with 
HFmrEF had the greatest variability (up and down) in 
LVEF but change in LVEF was not associated with survival, 
except when patients actually evolve to HFpEF. The clas-
sification of patients in HF with preserved, mid-ranged 
and reduced LVEF is not static and thus, the only reason 
to classify patients according to their LVEF would be to 
identify patients in whom disease-modifying therapies are 
useful to improve prognosis.
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